Are women appropriately represented and assessed in clinical trials submitted for marketing authorization? A review of the database of the European Medicines Agency

International Journal of Clinical Pharmacology and Therapeutics

Volumn 45, Issue 9, 2007, Pages 477-484

  Müllner, Marcus ^a   Vamvakas, S ^b   Rietschel, M ^b   van Zwieten Boot, B J ^c  

^a AUSTRIAN AGENCY FOR HEALTH AND FOOD SAFETY   (Austria)

^b EUROPEAN MEDICINES AGENCY   (United Kingdom)

^c College Ter Beoordeling van Geneesmiddelen ^*  (Netherlands)

Author keywords

Gender bias; Marketing authorization; Medicinal products; Regulatory affairs

Indexed keywords

ANTICOAGULANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NEUROLEPTIC AGENT; PLACEBO;

ACUTE HEART INFARCTION; ALLERGIC CONJUNCTIVITIS; CLINICAL RESEARCH; CLINICAL TRIAL; DIABETES MELLITUS; DRUG APPROVAL; EUROPE; GENDER BIAS; HEPATITIS B; HUMAN; HYPERTENSION; RESEARCH SUBJECT; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA;

EID: 34548661951     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP45477     Document Type: Review

References (28)

1. Bandyopadhyay S, Bayer AJ, O'Mahony MS. Age and gender bias in statin trials. QJM. 2001; 94: 127-132.
2. van Bergen PF, Jonker JJ, Molhoek GP, van der Burgh PH, van Domburg RT, Deckers JW, Hofman A. Characteristics and prognosis of non-participants of a multi-centre trial of long-term anticoagulant treattnent after myocardial infarction. Int J Cardiol. 1995; 49: 135-141.
3. Council regulation (EEC) No 2309/93 of 22 July 1993 laying down Community procedures for the authorization and supervision of medicinal products for human and veterinary use and establishing a European Agency for the Evaluation of Medicinal Products. Official Journal L 214. 24/8/ 1993; 1-21.
4. Ebert SN, Liu XK, Woosley RL. Female gender as a risk factor for drug-induced cardiac arrhythmias: evaluation of clinical and experimental evidence. J Womens Health. 1998; 7: 547-557.
5. Evelyn B, Toigo T, Pohl D, Gray K, Robins B, Ernat J. Women's participation in clinical trials and gender related labelling: a review of new molecular entities approved 1995-1999. US Food and Drug Administration, Center for Drug Evaluation and Research. June 2001; www.fda.gov/cder/reports/womens_health/women_clin_trials.htm (accessed 25.4.2007)
6. Food and Drug Administration. Guideline for the study and evaluation of gender differences in the clinical evaluation. Federal Register, Vol. 58, No. 139, July 22, 1993; www.fda.gov/cder/guidance/ old036fn.pdf (accessed 16.11.2004)
7. Gurwitz JH, Col NF, Avorn J. The exclusion of the elderly and women from clinical trials in acute myocardial infarction. JAMA. 1992; 268: 1417-1422.
8. Harris DJ, Douglas PS. Enrollment of women in cardiovascular clinical trials Raided by the National Heart, Lung, and Blood Institute. N Engl J Med 2000; 343: 475-480.
9. Hoosain M, Jewkes R, Maphumulo S. Gender audit of health research - 10 years of the South African Medical Journal. S Afr Med J. 1998; 88: 982-985.
10. Hutchins LF, Unger JM, Crowley JJ, Coltman CA, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999; 341: 2061-2067.
11. ICH harmonized tripartite guideline. Statistical principles for clinical trials. 1998. www.ich.org [accessed 21.1.2005].
12. Kinney EL, Trautmann J, Gold JA, Vesell ES, Zelis R. Underrepresentation of women in new drug trials. Ann Intem Med. 1981; 95: 495-499.
13. Lee PY, Alexander KP, Hammill BG, Pasquali SK, Peterson ED. Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA. 2001; 286: 708-713.
14. Martin R, Biswas PN, Freemande SN et al. Age and sex distribution of suspected adverse drug reactions to newly marketed drugs in general practice in England: analysis of 48 cohort studies. Br J Clin Pharmacol. 1998; 46: 505-511.
15. Maynard C, Selker HP Beshansky JR, Griffith JL, Schmid CH, Califf RM, D'Agostino RB, Laks MM, Lee KL, Wagner GS, Weaver WD. The exclusion of women from clinical trials of thrombolytic therapy: implications for developing the thrombolytic predictive instrument database. Med Decis Making. 1995; 15: 38-43.
16. Meibohm B, Beierle I, Derendorf H. How important are gender differences in pharmacokinetics? Clin Pharmacokinet. 2002; 41: 329-342.
17. Meinert CL, Gilpin AK, Unalp A, Dawson C. Gender representation in trials. Control Clin Trials. 2000; 21: 462-475.
18. Meinert CL, Gilpin AK. Estimation of gender bias in clinical trials. Stat Med. 2001; 20: 1153-1164.
19. Merkatz RB, Temple R, Subel S, Feiden K, Kessler DA. Women in clinical trials of new drugs. A change in Food and Drug Administration policy. The Working Group on Women in Clinical Trials. N Engl J Med. 1993; 329: 292-296.
20. Mohr P, Czobor P. Subject selection for the placebo- and comparator-controlled trials of neuroleptics in schizophrenia. J Clin Psychopharmacol. 2000; 20: 240-245.
21. Ramasubbu K, Gurm H, Litaker D. Gender bias in clinical trials: do double standards still apply? J Womens Health Gend Based Med. 2001; 10: 757-764.
22. Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. Official Journal L 136. 30/4/2004; 1-33.
23. Rychtarik RG, McGillicuddy NB, Connors GJ, Whitney RB. Participant selection biases in a randomized clinical trial of alcoholism treatment settings and intensities. Alcohol Clin Exp Res. 1998; 22: 969-973
24. Schnabel M, Schmidt T, Tuschen S, Leppek R, Vassiliou T, Schmidt M, Gotzen L, Kaluza G. Selection of subjects: a problem of clinical trials in traumatology. Selection effects and the problem of representation as exemplified by a prospective randomized trial on whiplash injuries. Unfallchirurg. 2001; 104: 716-726.
25. Sloan JA, Goldberg RM, Sargent DJ et al. Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol. 2002; 20: 1491-1498.
26. Thürmann PA, Hompesch BC. Influence of gender on the pharmacokinetics and pharmacodynamics of drugs. Int J Clin Pharmacol Ther. 1998; 36: 586-590.
27. Vidaver RM, Lafleur B, Tong C, Bradshaw R, Marts SA. Women subjects in NIH-funded clinical research literature: lack of progress in both representation and analysis by sex. J Womens Health Gend Based Med. 2000; 9: 495-504.
28. Wieringa NF, de Graeff PA, van der Werf GT, Vos R. Cardiovascular drugs: discrepancies in demographics between pre- and post-registration use. Eur J Clin Pharmacol. 1999; 55: 537-544.